Testing and Treating Mycobacterium tuberculosis Infection.
Diagnosis
Mycobacterium tuberculosis
Treatment
Tuberculosis
Journal
The Medical clinics of North America
ISSN: 1557-9859
Titre abrégé: Med Clin North Am
Pays: United States
ID NLM: 2985236R
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
entrez:
24
10
2022
pubmed:
25
10
2022
medline:
27
10
2022
Statut:
ppublish
Résumé
After infection with Mycobacterium tuberculosis, a minority of individuals will progress to tuberculosis disease (TB). The risk is higher among persons with well-established risk factors and within the first year after infection. Testing and treating individuals at high risk of progression maximizes the benefits of TB preventive therapy; avoiding testing of low-risk persons will limit potential harms. Several treatment options are available; rifamycin-based regimens offer the best efficacy-safety balance. In this review, we present an overview of the diagnosis and treatment of TB infection, and summarize common clinical scenarios.
Identifiants
pubmed: 36280337
pii: S0025-7125(22)00094-3
doi: 10.1016/j.mcna.2022.08.001
pii:
doi:
Substances chimiques
Antitubercular Agents
0
Rifamycins
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
929-947Informations de copyright
Copyright © 2022 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Disclosure The authors have nothing to disclose.